Business
InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019
InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019 ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 12, 2019\n\n\n\nTSX:INOTCQX:IMLFF\n VANCOUVER, March 12, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a R&D pipeline of medications targeting diseases with high unmet medical needs, today announced that InMed's President and Chief Executive Officer, Eric A. Adams, will be presenting on a panel discussion entitled \"Cannabinoid Pharmaceuticals\" at the 31st Annual ROTH Conference on Tuesday, March 19, 2019, at 10:00 AM PT, in Orange County, California.\nAbout InMed:InMed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids, as well as a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs.  The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.  For more information, visit www.inmedpharma.com.\nCautionary Note Regarding Forward-Looking Information:This news release contains \"forward-looking information\" and \"forward-looking statements\"  (collectively, \"forward-looking information\") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a R&D pipeline of medications targeting diseases with high unmet medical needs; pres...